Minerva Surgical to Announce First Quarter 2022 Financial Results
Minerva Surgical, Inc. (Nasdaq: UTRS) has announced the release of its first quarter 2022 financial results scheduled for May 11, 2022. The company specializes in treating Abnormal Uterine Bleeding (AUB) and will hold a conference call at 1:30 p.m. PT to discuss these results and recent highlights. Interested participants can join the call via telephone or through a live webinar accessible on the company's website. Minerva Surgical focuses on minimally invasive solutions for women's uterine healthcare needs, providing alternatives to hysterectomies for treating AUB.
- Scheduled financial results announcement on May 11, 2022, showcasing transparency.
- Focus on minimally invasive solutions addresses women's health issues effectively.
- None.
SANTA CLARA, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a woman’s health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that it will release its first quarter 2022 financial results on Wednesday, May 11, 2022. In conjunction with the release, the company will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
Interested parties may access the live call via telephone by dialing (877) 804-7316 for domestic callers or (629) 228-0696 for international callers, using conference ID: 5665795. The live webinar of the call may be accessed by visiting the Recent Events section of the company’s website at http://ir.minervasurgical.com. A replay of the webinar will be available on the Company’s website shortly after the conclusion of the call.
About Minerva Surgical, Inc.
Minerva Surgical is a commercial-stage medical technology company focused on developing, manufacturing, and commercializing minimally invasive solutions to meet the distinct uterine healthcare needs of women. The Company has established a broad product line of commercially available, minimally invasive alternatives to hysterectomy, which are designed to address the most common causes of Abnormal Uterine Bleeding (AUB) in most uterine anatomies. The Minerva Surgical solutions can be used in a variety of medical treatment settings and aim to address the drawbacks associated with alternative treatment methods and to preserve the uterus by avoiding unnecessary hysterectomies.
MEDIA CONTACT
Mike Clapper
mike.clapper@minervasurgical.com
804-295-7676
INVESTOR RELATIONS CONTACT
Caroline Corner
investors@minervasurgical.com
415-202-5678
RELATED LINKS
https://www.minervasurgical.com
FAQ
When will Minerva Surgical release Q1 2022 financial results?
What is the purpose of the conference call on May 11, 2022?
How can I access the financial results call for UTRS?
What is Minerva Surgical's focus in women's health?
